The stock will cease trading following delisting, and FOLD shareholders have been paid out in full. No further corporate actions are expected as Amicus operates as a private subsidiary of BioMarin. Monitor BioMarin's financial reports for integration updates.
How the stock moved after the report
NEUTRAL VIEWSTOCK AT ENTRY AT T+1- T+0 · Apr 27 $14.49entry
- T+1 · 7mo ago 0.00%α +0.49% · $14.49
- T+5 · due 7mo ago Pending
- T+20 · due 6mo ago Pending
- T+60 · due 4mo ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Amicus Therapeutics completed its acquisition by BioMarin Pharmaceutical, resulting in a change of control, delisting from Nasdaq, and termination of its credit agreement. All directors and executive officers resigned, with BioMarin appointing new leadership. Shareholders received $14.50 per share in cash.
Key Facts
- Merger with BioMarin Pharmaceutical completed on April 27, 2026, with Amicus becoming a wholly owned subsidiary.
- Shareholders received $14.50 per share in cash as merger consideration.
- Company common stock to be delisted from Nasdaq; Form 25 filed for deregistration.
- All nine directors and five executive officers resigned; BioMarin appointees took over leadership roles.
- Amended and restated certificate of incorporation reduces authorized shares to 100 common shares.
- Credit agreement with Blackstone and Wilmington Trust terminated; all debt repaid.
Financial Impact
$14.50 per share cash payment to shareholders; full repayment of outstanding credit facility
Risk Factors
- Loss of public market liquidity for former shareholders
- Integration risks within BioMarin's organization
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-016968 |
| Document: ef20071351_8k.htm | 0001140361-26-016968 |
| Document: ef20071351_ex3-1.htm | 0001140361-26-016968 |
| Document: 0001140361-26-016968-index-headers.html | 0001140361-26-016968 |
| Document: 0001140361-26-016968-index.html | 0001140361-26-016968 |
| Document: 0001140361-26-016968.txt | 0001140361-26-016968 |
Track record
3 reports on FOLD
Filters
- May 7, 202627w ago 15-12G Neutral 4/10 No price data
- Apr 27, 202629w ago 8-K Neutral 9/10 Viewing Entry $14.49 No price data
- Apr 23, 202629w ago 8-K Neutral 6/10 Entry $14.49 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers